Prosecution Insights
Last updated: May 29, 2026

Janux Therapeutics Inc.

7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Portfolio Summary

7
Total Pending OAs
5
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
2
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due ≤ 30 days (2)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (29%)
1
Easy (14%)
4
Unknown (57%)

Rejection Statute Mix

BucketCases
§103 only1 (14%)
§112 only1 (14%)
Double-patenting + other1 (14%)
No statute on record4 (57%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
YAO, LEI 1 60.0% +65.6%
SAOUD, CHRISTINE J 1 57.8% +37.9%
CUNNINGCHEN, KATHLEEN MARY 1 63.8% +59.5%
TAYLOR, LIA ELAN 1 64.0% +28.2%
FAUST, AMBER KATHLEEN 1 62.3% +50.3%
JUEDES, AMY E 1 44.5% +41.0%
LUNDE, GRACE HENRY 1 63.6% +37.5%

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
17616281 COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS LUNDE, GRACE HENRY 127d overdue
18314077 COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS CUNNINGCHEN, KATHLEEN MARY 38d overdue
18256276 HALF-LIFE EXTENDING COMPOSITIONS AND METHODS SAOUD, CHRISTINE J 37d overdue
18256278 PEPTIDE COMPOSITIONS AND METHODS FOR ANTI-CD3 BINDING DOMAINS YAO, LEI 9d
18031724 ANTIBODIES TARGETING PSMA AND CD3 AND USES THEREOF JUEDES, AMY E 27d
18249886 MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF TAYLOR, LIA ELAN 33d
18249879 ANTIBODIES TARGETING HER2 AND CD3 AND USES THEREOF FAUST, AMBER KATHLEEN 61d

Top Art Units

Art UnitApps
1641 2
1642 1
1645 1
1646 1
1643 1
1644 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18256278 PEPTIDE COMPOSITIONS AND METHODS FOR ANTI-CD3 BINDING DOMAINS YAO, LEI 1642 Other Non-Final OA 9d Pending Jun 07, 2023
18256276 HALF-LIFE EXTENDING COMPOSITIONS AND METHODS SAOUD, CHRISTINE J 1645 Other Non-Final OA 37d overdue Pending Jun 07, 2023
18314077 COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS CUNNINGCHEN, KATHLEEN MARY 1646 Other Non-Final OA 38d overdue Pending May 08, 2023
18249886 MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF TAYLOR, LIA ELAN 1641 §103 Non-Final OA 33d Pending Apr 20, 2023
18249879 ANTIBODIES TARGETING HER2 AND CD3 AND USES THEREOF FAUST, AMBER KATHLEEN 1643 DPOther Final Rejection 61d Pending Apr 20, 2023
18031724 ANTIBODIES TARGETING PSMA AND CD3 AND USES THEREOF JUEDES, AMY E 1644 §112 Final Rejection 27d Pending Apr 13, 2023
17616281 COMPOSITIONS AND METHODS RELATING TO TUMOR ACTIVATED T CELL ENGAGERS LUNDE, GRACE HENRY 1641 Other Non-Final OA 127d overdue Pending Dec 03, 2021

Managing Janux Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month